1. Protein Tyrosine Kinase/RTK
  2. FAK

FAK

FAK (Focal Adhesion Kinase or PTK2) is a focal adhesion-associated protein kinase involved in cellular adhesion and spreading processes. It has been shown that when FAK was blocked, breast cancer cells became less metastatic due to decreased mobility. FAK is found concentrated in the focal adhesions that form among cells attaching to extracellular matrix constituents. FAK is a member of the FAK subfamily of protein tyrosine kinases that included PYK2 but lacks significant sequence similarity to kinases from other subfamilies. With the exception of certain types of blood cells, most cells express FAK. FAK tyrosine kinase activity can be activated, which plays a key important early step in cell migration. FAK activity elicits intracellular signal transduction pathways that promote the turn-over of cell contacts with the extracellular matrix, promoting cell migration.

FAK Related Products (13):

Cat. No. Product Name Effect Purity
  • HY-13917
    PND-1186 Inhibitor 99.71%
    PND-1186 is a substituted pyridine reversible inhibitor of FAK activity with IC50 of 1.5 nM in vitro.
  • HY-12289
    Defactinib Inhibitor 99.32%
    Defactinib is a novel FAK inhibitor, which inhibits FAK phosphorylation at the Tyr397 site in a time- and dose-dependent manner.
  • HY-100498
    GSK2256098 Inhibitor 99.35%
    GSK2256098 is a selective FAK kinase inhibitor, which inhibits growth and survival of pancreatic ductal adenocarcinoma cells.
  • HY-10461
    PF-573228 Inhibitor 98.72%
    PF-573228 is a potent and selective FAK inhibitor with IC50 of 4 nM for purified recombinant catalytic fragment of FAK.
  • HY-10459
    PF-562271 Inhibitor 99.36%
    PF-562271 is a potent ATP-competitive, reversible inhibitor of FAK and Pyk2 kinase, with IC50 of 1.5 nM and 13 nM, respectively.
  • HY-B1305
    Chloropyramine hydrochloride Inhibitor 99.30%
    Chloropyramine hydrochloride is a histamine receptor H1 antagonist which can also inhibit the biochemical function of VEGFR-3 and FAK.
  • HY-12444
    Y15 Inhibitor >98.0%
    Y15 is a direct and specific inhibitor of FAK auto-phosphorylation.
  • HY-13203
    NVP-TAE 226 Inhibitor 98.98%
    NVP-TAE 226 is a dual tyrosine kinase inhibitor of FAK (IC50=5.5 nM) and IGF-IR (mean IC50=0.14 μM).
  • HY-15841
    CEP-37440 Inhibitor 99.87%
    CEP-37440 is a novel potent and selective Dual FAK/ALK inhibitor with IC50 s of 2.3 nM (FAK) and 120 nM(ALK cellular IC50 in 75% human plasma).
  • HY-10460
    PF-431396 Inhibitor 99.40%
    PF-431396 is dual focal adhesion kinase (FAK) and proline-rich tyrosine kinase 2 (PYK2) inhibitor (IC50 values are 2 and 11 nM respectively), PF-431396 has a Kd value of 445 nM for BRD4.
  • HY-10458
    PF-562271 besylate Inhibitor 98.31%
    PF-562271 (besylate) is a potent, ATP-competitive, reversible inhibitor of FAK and Pyk2 kinase with IC50 of 1.5 nM and 13 nM, and has > 100-fold selectivity against other protein kinases, except for some CDKs.
  • HY-19376
    NAMI-A Inhibitor >98.0%
    NAMI-A is a ruthenium-based drug characterised by the selective activity against tumour metastases, inhibits the adhesion and migration.
  • HY-12289A
    Defactinib hydrochloride Inhibitor 99.11%
    Defactinib hydrochloride is a novel FAK inhibitor, which inhibits FAK phosphorylation at the Tyr397 site in a time- and dose-dependent manner.